{"data":[{"dar_ID":10013,"expiration_date":"2027-06-25 21:11:43","approval_date":"2026-06-25 21:11:43","initial_approval_date":"2018-10-29 14:09:35","project_name":"ADSP Data Analysis","status_name":"Approved","first_name":"Lindsay","last_name":"Farrer","institution":"Boston University","dataset_accessions":["NG00167"],"publications":["40407102","40528303","41428483","41040715"],"dar_publications":["40407102","40528303","41428483","41040715","39428839","39428694","39444005","38746629","38418088","38263370","36809323","37051669","37260021","37578203","37930705","35210353","36411364","36539198","35258170","34152079","33804025","31180460","30924900","30108311","30503768"],"researchSTMT":"As part of the Consortium for Alzheimers Sequence Analysis (CASA: NIA grant UF1-AG047133), we  plan to analyze whole exome and whole genome sequence data generated from subjects with Alzheimer's disease (AD) and elderly normal controls. These data will be generated by the National Human Genome Institute Large-Scale Sequence Program. The goal of the planned analyses is to identify genes that have alleles that protect against or increase susceptibility to AD. We will evaluate variants detected in the sequence data for association with AD to identify protective and susceptibility alleles using the whole exome case-control data. We will also evaluate sequence data from multiplex AD families to identify variants associated with AD risk and protection, and evaluate variant co-segregation with AD. The family data will be whole genome data. The family-based data will be used to inform the cases control analysis and visa versa. We also will focus on structural variants (insertion-deletions, copy number variants, and chromosomal rearrangements). Evaluation of structural variants will involve both whole genome and whole exome data. Structural variants will be analyzed with single nucelotide variants detected and analyzed in the case-control and family-based data.","ntResearchSTMT":"We are attempting to identify all the inherited elements that contribute to Alzheimer's disease risk. To do this we will analyze DNA sequence data from subjects with Alzheimer's disease and elderly subjects who are cognitively normal. The sequence data from these 2 groups will be compared to identify differences that contribute to the risk of developing Alzheimer's disease of that protect against Alzheimer's disease. These DNA differences can be at a single site in the genetic code, or can span multiple sites, changing the copy number of DNA sequences. Both types of genetic variants will be examined.   "},{"dar_ID":12038,"expiration_date":"2027-02-10 12:59:57","approval_date":"2026-02-10 12:59:57","initial_approval_date":"2026-02-10 12:59:57","project_name":"GADIR","status_name":"Approved","first_name":"Victoria","last_name":"Fernandez","institution":"ACE Alzheimer Center","dataset_accessions":["NG00167"],"publications":[],"dar_publications":[],"researchSTMT":"The objective of this study is to contribute to our understanding of neurodegenerative diseases by examining the genetic contributors of major dementia neuropathological hallmarks (amyloid-β deposition, tau pathology, TDP-43, hippocampal sclerosis, Lewy body pathology, and cerebrovascular disease, among others. We will generate the largest Iberian database(N=3500) of neuropathologically curated brains (Aim 1) with a subset of those (N≈350) undergoing deep digital phenotyping (Aim 3). We will generate an associated genetic map (Aim 2) order to elucidate how common and rare genetic variants contribute to specific pathologies. We additionally aim to determine how polygenic risk scores (PRS) and pathway-specific PRS correspond to single and mixed neuropathological profiles, and to clarify the genetic architecture driving co-pathologies that frequently complicate clinical diagnosis. Eventually, we will replicate and fine-map our findings (Aim 4) leveraging available datasets at NIAGADS and other public repositories.\n\nOur analysis plan includes genome-wide association testing of ordinal, binary, and quantitative neuropathological traits; rare-variant burden analyses for coding and non-coding regions; PRS and pathway-PRS modeling across multiple dementia-related diseases; unsupervised clustering to identify variant sets defining specific endophenotypes; and pathway and network analyses to interpret significant signals. Colocalization and functional annotation approaches will integrate genomic findings with transcriptomic and proteomic resources.\n\nData obtained from NIAGADS will be used to strengthen replication, broaden meta-analytic power, validate associations across independent neuropathology cohorts, and support functional interpretation using available genetic, expression, and multi-omic datasets. All analyses will use de-identified data in compliance with ethical and data-sharing standards.","ntResearchSTMT":"Dementia is an immensely challenging and prevalent condition, deeply impacting the lives of over 55 million individuals worldwide. While Alzheimer's disease stands as the most commonly recognized form of dementia, there exist other conditions that present comparable symptoms but distinct underlying pathological characteristics. To provide more effective support to patients and their families, we need to better understand the genetic causes associated to each of these brain pathologies, and to develop advanced tools for early classification and diagnosis. This grant proposal aims to tackle these challenges by establishing the largest Iberian (Spanish and Portuguese) database of dementia neuropathological cases, marked by a modernized and standardized neuropathological classification alongside comprehensive genomic data. Our goal is to delve further into the genetic architecture underpinning these pathological features and to refine existing risk assessment tools for more accurate diagnoses."},{"dar_ID":12573,"expiration_date":"2027-10-30 19:58:24","approval_date":"2026-10-30 19:58:24","initial_approval_date":"2026-10-30 19:58:24","project_name":"ADAPTT","status_name":"Approved","first_name":"Jonathan","last_name":"Haines","institution":"Case Western Reserve University","dataset_accessions":["NG00167"],"publications":[],"dar_publications":[],"researchSTMT":"Objectives: The overall goal of the planned analyses for ADAPTT is to better characterize the known genetic loci that are associated with AD/ADRD to identify the most probable functional elements responsible for the association. Most of these known associations have not been assigned to specific genes or functional variants.\nWe plan to analyze DNA variation from SNP array, whole exome and whole genome sequence data generated from participants that span the spectrum of dementia (with a focus on Alzheimer disease (AD) but also including MCI and related dementias [ADRD]) and participants without dementia (typically considered “controls”). \n\nStudy Design: We will evaluate these known loci, including the many genes underlying these associations, by integrating available genetic data, genomic data, in silico annotations, and multi-omic data using multiple different computational approaches. Our approaches will be sensitive to the different study designs of the contributing datasets (e.g. cohort studies, case-control studies, family-based studies). We will also examine a small number of these loci, prioritized by our analyses, using molecular genomic methods to better characterize the molecular mechanisms underlying the associations.\n\nCollaboration: This is a collaboration with Drs. Martin, Pericak-Vance, and Vance at the University of Miami.\n\n","ntResearchSTMT":"We are attempting to identify the inherited elements that contribute to Alzheimer disease risk. To do this we will analyze DNA sequence data from participants with Alzheimer disease and related dementias along with subjects who are cognitively normal. There are many known regions of the human genome that are associated with AD/ADRD risk, but the actual DNA sequence variations that are responsible for those associations remain unknown. Our goal is to use statistical and computer methods to identify the underlying responsible variations. For a small number of these, we will directly examine the biological mechanisms that help explain how those variations impact AD/ADRD.\n\n"},{"dar_ID":11542,"expiration_date":"2027-03-31 19:56:47","approval_date":"2026-03-31 19:56:47","initial_approval_date":"2025-01-07 19:16:05","project_name":"Genetics of Alzheimer's Disease and Endophenotypes","status_name":"Approved","first_name":"M. Ilyas","last_name":"Kamboh","institution":"University of Pittsburgh","dataset_accessions":["NG00167"],"publications":[],"dar_publications":[],"researchSTMT":"Objectives: \nWe are requesting access to the NIAGADS datasets to augment our ongoing studies on the genetics of Alzheimer’s disease (AD) and AD-related endophenotypes being carried out by Kamboh and his group since 1995.  We are doing GWAS using array genotypes, whole-exome sequencing and whole-genome sequencing on datasets derived from University of Pittsburgh ADRC and ancillary population-based longitudinal studies on dementia and biomarkers. Different available phenotypes include AD and non-AD dementia, age-at-set, disease progression and survival, neuroimaging, cognitive decline, plasma biomarkers for the core ATN and non-ATN pathologies. We also plan to expand on gene-gene interaction and sex-stratified analyses which require the actual genotype data. The NIAGADS datasets will be used for replication and meta-analysis, and for gene-gene interaction and sex-stratified analyses. \nStudy Design: \nA case-control design will incorporate a diverse cohort of individuals with AD and age-matched controls. For quantitative traits (neuroimaging and plasma biomarkers, cognitive performance measures, indicators of disease progression), linear regression analyses will be performed to identify genetic loci. To ensure the findings are robust and inclusive, participants from diverse demographic backgrounds will be included, enabling the exploration of potential genetic variations across populations.\nAnalysis Plan: \nWe will conduct GWAS and targeted analyses on candidate genes on different AD and AD-related phenotypes. Primary phenotypic variables include AD disease status, age-at-onset, last age for controls, APOE genotype, cognitive decline trajectories, sex, and race. Analyses will evaluate the influence of specific genetic variants on disease risk, cognitive performance, and biomarker levels, considering both individual and interactive effects of the APOE genotype. Results will be adjusted for potential confounders, such as demographic factors, to ensure valid associations. Detail analytical methods are described in our published papers for case-control (PMID: 32651314;35694926), quantitative traits (PMID: 30361487;37666928), and cognitive decline (PMID: 37089073; 30954325).\n","ntResearchSTMT":"Our research group at the University of Pittsburgh (Pitt), has been working on the genetics of Alzheimer’s disease (AD) and AD-related endophenotypes for almost three decades, on data derived largely from the University of Pittsburgh  Alzheimer’s Disease Research Center and ancillary dementia studies. We are requesting access to the NIAGADS genotype and phenotype datasets to augment our sample size to increase power to detect novel genetic associations with AD and related endophenotypes."},{"dar_ID":10085,"expiration_date":"2027-03-13 19:47:00","approval_date":"2026-10-21 19:47:42","initial_approval_date":"2020-10-14 14:30:45","project_name":"Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems approaches","status_name":"Approved","first_name":"Sudha","last_name":"Seshadri","institution":"Glenn Biggs Institute for Alzheimer&#39;s and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX","dataset_accessions":["NG00167"],"publications":["41560352","41720779","42024100"],"dar_publications":["41560352","41720779","42024100","38511601","39428839","40084664","37923804","37322115","37333771"],"researchSTMT":"Objective: Utilize ADSP data sets to identify genes & specific genetic variants that confer risk for or protection from Alzheimer disease.\nAim 1: Using combined WGS/WES across the ADSP Discovery, Disc-Ext, and FUS Phases, including single nucleotide variants, small insertion/deletions, and structural variants. We will:\nAim 1a. Perform whole genome single variant and rare variant case/control association analyses of AD using ADSP and other available data;\nAim 1b. Target protective variant identification via association analysis using selected controls within the ADSP data and performing meta analysis across association results based on selected controls from non-ADSP data sets.\nAim 1c. Perform endophenotype analyses including cognitive function measures, hippocampal volume and circulation beta-amyloid ADSP data in subjects for which these measures are available. Meta analysis will be conducted across ADSP and non-ADSP analysis results.\nAim 2: To leverage ethnically-diverse and admixed populations to identify AD variants we will:\nAim 2a. Estimate and account for global and local ancestry in all analyses;\nAim 2b. Perform admixture mapping in samples of admixed ancestry; and\nAim 2c. Perform ethnicity-specific and trans-ethnic meta-analyses.\nAim 3: To identify putative therapeutic targets through functional characterization of genes and networks via bioinformatics, integrative omics analyses. We will:\nAim 3a. Annotate variants with their functional consequences using bioinformatic tools and publicly available “omics” data.\nAim 3b. Prioritize results, group variants with shared function, and identify key genes functionally related to AD via weighted association analyses and network approaches.\nAnalyses will be performed in coordination with the following PIs. Coordination will involve sharing expertise, analysis plans or analysis results. No individual level data will be shared across institutions. Philip De Jager, Columbia University; Eric Boerwinkle & Myriam Fornage, UT Health Science Center at Houston; Sudha Seshadri, UT Health Science Center at San Antonio; Ellen Wijsman, University of Washington; William Salerno, Baylor College of Medicine.","ntResearchSTMT":"This proposal seeks to analyze existing genetic sequencing data generated as part of the Alzheimer’s Disease Sequencing Project (ADSP) including the ADSP Follow-up Study (FUS) with the goal of identifying genes and specific changes within those genes that either confer risk for Alzheimer’s disease or provide protection from Alzheimer’s disease. Analytic challenges include analysis of whole genome sequencing data, appropriately accounting for population structure across European ancestry, Hispanic, and African American participants, and interpreting results in the context of other genomic data available."}]}